Inside informationEnglish
Press Release: Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticaria
The file is served by the AMF. We do not host a copy.
Document type
- Issuer
- Sanofi
- Filed
- 18/04/2025, 17:15
- Document type
- Inside information
- AMF sub-type
- Informations privilégiées
- Language
- English
- AMF reference
- 111152_20250418